A pilot study of immunization with interleukin-2 secreting allogeneic HLA-A2 matched renal cell carcinoma cells in patients with advanced renal cell carcinoma.
D000328:Adult; D000818:Animals; D000951:Antigens, Neoplasm / Q000032:analysis*; D002292:Carcinoma, Renal Cell / Q000453:epidemiology / Q000276:immunology / Q000473:pathology / Q000628:therapy*; D002985:Clinical Protocols; D015316:Genetic Therapy; D015789:HLA-A2 Antigen / Q000032:analysis*; D006801:Humans; D007111:Immunity, Cellular; D007155:Immunologic Factors / Q000008:administration & dosage / Q000235:genetics / Q000378:metabolism / Q000627:therapeutic use*; D016233:Immunotherapy, Active; D015994:Incidence; D007258:Informed Consent; D007376:Interleukin-2 / Q000008:administration & dosage / Q000235:genetics / Q000378:metabolism / Q000627:therapeutic use*; D007680:Kidney Neoplasms / Q000453:epidemiology / Q000276:immunology / Q000473:pathology / Q000628:therapy*; D051379:Mice; D010865:Pilot Projects; D011323:Primates; D011993:Recombinant Fusion Proteins / Q000008:administration & dosage / Q000235:genetics / Q000378:metabolism / Q000627:therapeutic use*; D012449:Safety; D016879:Salvage Therapy; D014184:Transplantation, Homologous; D014407:Tumor Cells, Cultured / Q000276:immunology / Q000637:transplantation*
D000951:Antigens, Neoplasm; D015789:HLA-A2 Antigen; D007155:Immunologic Factors; D007376:Interleukin-2; D011993:Recombinant Fusion Proteins